David M Applegate

US Patent:

20120078362, Mar 29, 2012

Filed:

May 18, 2010

Appl. No.:

13/321144

Inventors:

David Haffner - Mission Viejo CA, US
Ken Curry - Oceanside CA, US
Harold Heitzmann - Irvine CA, US
David Applegate - Laguna Hills CA, US

Assignee:

DOSE MEDICAL CORPORATION - Laguna Hills CA

International Classification:

A61F 2/16

US Classification:

623 613

Abstract:

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

US Patent:

20130090534, Apr 11, 2013

Filed:

Sep 12, 2012

Appl. No.:

13/612545

Inventors:

Thomas W. Burns - Dana Point CA, US
Harold A. Heitzmann - Irvine CA, US
Kenneth Martin Curry - Oceanside CA, US
David S. Haffner - Mission Viejo CA, US
David Applegate - Palm Springs CA, US
Bruce Nogales - Raleigh NC, US

International Classification:

A61B 3/16
H01M 8/16
A61B 5/00
A61B 5/145
A61B 5/1473

US Classification:

600301, 600398, 600558, 600300, 429401

Abstract:

An implantable intraocular physiological sensor for measuring intraocular pressure, glucose concentration in the aqueous humor, and other physiological characteristics. The implantable intraocular physiological sensor may be at least partially powered by a fuel cell, such as an electrochemical glucose fuel cell. The implantable intraocular physiological sensor may wirelessly transmit measurements to an external device. In addition, the implantable intraocular physiological sensor may incorporate aqueous drainage and/or drug delivery features.

US Patent:

20130289467, Oct 31, 2013

Filed:

Nov 22, 2011

Appl. No.:

13/989037

Inventors:

David Haffner - Mission Viejo CA, US
Ken Curry - Oceanside CA, US
Harold Heitzmann - Irvine CA, US
David Applegate - Laguna Hills CA, US

International Classification:

A61F 9/00
A61F 9/007

US Classification:

604 8, 604294, 604290

Abstract:

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

US Patent:

20220330819, Oct 20, 2022

Filed:

Jun 20, 2022

Appl. No.:

17/844497

Inventors:

- San Clemente CA, US
Harold A. Heitzmann - Irvine CA, US
Kenneth Martin Curry - Oceanside CA, US
David S. Haffner - Mission Viejo CA, US
David Applegate - Palm Springs CA, US
Bruce Nogales - Raleigh NC, US

International Classification:

A61B 3/16
A61B 5/00
A61B 5/07
A61B 5/11
A61B 5/145
G16H 10/60
G16H 20/10
G16H 50/30
A61B 5/1473
H01M 8/16

Abstract:

An implantable intraocular physiological sensor for measuring intraocular pressure, glucose concentration in the aqueous humor, and other physiological characteristics. The implantable intraocular physiological sensor may be at least partially powered by a fuel cell, such as an electrochemical glucose fuel cell. The implantable intraocular physiological sensor may wirelessly transmit measurements to an external device. In addition, the implantable intraocular physiological sensor may incorporate aqueous drainage and/or drug delivery features.

US Patent:

20210015662, Jan 21, 2021

Filed:

Oct 1, 2020

Appl. No.:

17/061372

Inventors:

- San Clemente CA, US
Kenneth M. Curry - San Clemente CA, US
Harold A. Heitzmann - San Clemente CA, US
David Applegate - San Clemente CA, US

International Classification:

A61F 9/00
A61F 9/007
A61K 9/00
A61K 9/20

Abstract:

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

US Patent:

20190053704, Feb 21, 2019

Filed:

Jul 11, 2018

Appl. No.:

16/032945

Inventors:

- San Clemente CA, US
Harold A. Heitzmann - Irvine CA, US
Kenneth Martin Curry - Oceanside CA, US
David S. Haffner - Mission Viejo CA, US
David Applegate - Palm Springs CA, US
Bruce Nogales - Raleigh NC, US

International Classification:

A61B 3/16
H01M 8/16
A61B 5/00
A61B 5/1473
A61B 5/145
A61B 5/11
A61B 5/07

Abstract:

An implantable intraocular physiological sensor for measuring intraocular pressure, glucose concentration in the aqueous humor, and other physiological characteristics. The implantable intraocular physiological sensor may be at least partially powered by a fuel cell, such as an electrochemical glucose fuel cell. The implantable intraocular physiological sensor may wirelessly transmit measurements to an external device. In addition, the implantable intraocular physiological sensor may incorporate aqueous drainage and/or drug delivery features.

US Patent:

20170281409, Oct 5, 2017

Filed:

Jun 5, 2017

Appl. No.:

15/613994

Inventors:

- San Clemente CA, US
Kenneth M. Curry - San Clemente CA, US
Harold A. Heitzmann - San Clemente CA, US
David Applegate - San Clemente CA, US

International Classification:

A61F 9/00
A61K 9/00
A61K 9/20
A61F 9/007

Abstract:

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.